Anavex Life Sciences Corp (AVXL)

[bas2020]

Investors are really sick of FUDsters saying that the data are inconclusive, suggesting the trials have failed. Just because FUDsters state claims of "cherry picking" or "moved goalposts" doesn't make it true.

Here again are the astonishing data of the P2b/3 AD trial, that met all endpoints and where patients functionally improved...

• Odds Ratio of ADAS-Cog meaningful improvement in cognition at threshold of -0.5 points or less (90% CI) 1.839 (1.17, 2.94) P = 0.015

• Odds Ratio of ADCS-ADL meaningful improvement in function at threshold of +3.5 points or higher (90% CI) 2.67 (1.17, 6.13) P = 0.0255

• ANAVEX®2-73 treatment slowed cognitive decline by 45% compared to placebo at 48 weeks
• Mean difference in ADAS-Cog score change of -1.85 points

• Compared to placebo, ANAVEX®2-73 (blarcamesine) reduced clinical decline of cognition and function by 27% with mean score difference of -0.42 points (p=0.040) as measured by CDR-SB

• ADCS-Cog and CDR-SB (p < .025) proving further significance of stat. sig. improvements and trial success.

• Identification of two key biomarkers (Aß42/40 ratio and brain volume stabilization) for AA pathway option.

For FUDsters to continually deny these results is plain false shenanigans with a nefarious motive.